Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics

• Published in: Respirology (Carlton, Vic.) Vol. 28; no. 8; pp. 758 - 766
• Main Authors: Malik, Bilal, Bartlett, Nathan W., Upham, John W., Nichol, Kristy S., Harrington, John, Wark, Peter A. B.
• Format: Journal Article
• Language: English
• Published: Australia Wiley Subscription Services, Inc 01.08.2023; John Wiley & Sons, Ltd
• Subjects: Asthma; Asthma - drug therapy; Biological Products; Cell Proliferation; Cytokines - metabolism; GATA-3 protein; Humans; Immunity, Innate; Immunoglobulin E; Inflammation; Interleukin 6; Interleukin-13; Interleukin-5; Leukocytes (eosinophilic); Lymphocytes; Lymphoid cells; Monoclonal antibodies; Omalizumab; Original; ORIGINAL ARTICLES; Peripheral blood; Phenotypes; Pulmonary Eosinophilia; Respiratory diseases; Respiratory tract diseases; Thymic stromal lymphopoietin; Thymus; ILC2; type 2 innate lymphoid cell; proliferation; thymic stromal lymphopoietin receptor; type 2 cytokine; mepolizumab; severe asthma; omalizumab
• ISSN: 1323-7799; 1440-1843; 1440-1843
• DOI: 10.1111/resp.14506

Type 2 (T2) innate lymphoid cells (ILC2s) contribute to airway inflammation and disease in asthma. We hypothesize that ILC2s isolated from people with severe allergic and eosinophilic asthma would exhibit an enhanced T2 inflammatory activity that would be altered following treatment with mepolizumab...